{"product_id":"fluimucil-mucolitico-200-mg-30-bustine-granulato-senza-zucchero","title":"Fluimucil Mucolitico 200 mg 30 Sachets Sugar-free Granules","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of respiratory diseases characterized by dense and viscous hypersecretion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg effervescent tablets\u003c\/i\u003e Each tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: aspartame, glucose, sodium. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg granules for oral solution \u003c\/i\u003e Each sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: aspartame, glucose, lactose, sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg\/15 ml syrup\u003c\/i\u003e 15 ml of syrup contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 600 mg. Excipients with known effects: propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, sodium, sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, effervescent tablets\u003c\/i\u003e One tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sodium, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, buccal tablets:\u003c\/i\u003e One tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sorbitol, sodium, aspartame. \u003ci\u003e FLUIMUCIL MUCOLITIC 200 mg, granules for oral solution\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sucrose, glucose, sunset yellow (E110), lactose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg, granules for oral solution without sugar\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 200 mg. Excipients with known effects: sorbitol, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg, granules for oral solution\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 100 mg. Excipients with known effects: sucrose, sunset yellow (E110).\u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg, granules for oral solution without sugar\u003c\/i\u003e One sachet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 100 mg. Excipients with known effects: sorbitol, aspartame. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml, syrup\u003c\/i\u003e A 150 ml bottle contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: N-acetylcysteine 3,000 g (corresponding to 100 mg\/5 ml of syrup). Excipients with known effects: ethanol, methyl parahydroxybenzoate, propylene glycol, sodium benzoate, sodium. A 200 ml bottle contains: \u003cu\u003e Active ingredient\u003c\/u\u003e: N-acetylcysteine 4,000 g (corresponding to 100 mg\/5 ml of syrup). Excipients with known effects: ethanol, methyl parahydroxybenzoate, propylene glycol, sodium benzoate, sodium. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg granules for oral solution \u003c\/i\u003e Aspartame, Orange flavor (containing glucose and lactose), Sorbitol. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg effervescent tablets \u003c\/i\u003e Anhydrous citric acid, Lemon flavor (containing glucose), Aspartame, Sodium bicarbonate. \u003ci\u003eFLUIMUCIL MUCOLITIC 600 mg\/15 ml syrup 200 ml bottle\u003c\/i\u003eMethyl parahydroxybenzoate, Propyl parahydroxybenzoate, Sodium edetate, Carmellose, Sodium saccharin, Grenadine flavoring (containing propylene glycol), Strawberry flavoring (containing propylene glycol), Sorbitol, Sodium hydroxide, Purified water. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg buccal tablets\u003c\/i\u003e Anhydrous citric acid, sorbitol, mannitol, polyethylene glycol 6000, povidone, sodium bicarbonate, lemon flavouring, mandarin flavouring, aspartame, magnesium stearate, microcrystalline cellulose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg granules for oral solution without sugar \u003c\/i\u003e Sorbitol, aspartame, orange flavouring. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg granules for oral solution\u003c\/i\u003eOrange juice granules; Orange flavor (containing glucose and lactose); saccharin; sunset yellow (E 110); Sucrose. \u003ci\u003eFLUIMUCIL MUCOLITIC 200 mg effervescent tablets\u003c\/i\u003e \u003ci\u003eAnhydrous citric acid, sodium bicarbonate, lemon flavouring, aspartame.\u003c\/i\u003e \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg granules for oral solution\u003c\/i\u003eOrange juice granules; Orange flavour; Saccharin; E 110; Sucrose. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg granules for oral solution without sugar\u003c\/i\u003e Sorbitol; Aspartame; Orange flavour. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml syrup 150 ml bottle\u003c\/i\u003e Methyl parahydroxybenzoate, sodium benzoate, sodium edetate, sodium carboxymethyl cellulose, raspberry flavor (containing propylene glycol and ethanol), sodium saccharinate, sodium hydroxide, purified water. \u003ci\u003eFLUIMUCIL MUCOLITIC 100 mg\/5 ml syrup 200 ml bottle\u003c\/i\u003e Methyl parahydroxybenzoate, sodium benzoate, sodium edetate, sodium carboxymethylcellulose, sodium cyclamate, sucralose, raspberry flavor (containing propylene glycol and ethanol), sodium saccharinate, sodium hydroxide, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Children under 2 years of age. Pregnancy and breast-feeding (see section 4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eAdults\u003c\/u\u003e: 1 sachet of Mucolytic Fluimucil 200 mg granules for oral solution (with or without sugar) or 2 sachets of Mucolytic Fluimucil 100 mg (with or without sugar) 2-3 times a day. Fluimucil Mucolytic 200 mg, buccal tablets and effervescent tablets: 1 tablet 2-3 times a day. Fluimucil Mucolytic 100 mg\/5 ml, syrup: 10 ml of syrup (1 measuring spoon), equal to 200 mg of N-acetylcysteine, 2-3 times a day. Fluimucil Mucolytic 600 mg\/15 ml syrup, Fluimucil Mucolytic 600 mg effervescent tablets and Fluimucil Mucolytic 600 mg granules for solution: a 15 ml measuring spoon or an effervescent tablet or a sachet (preferably in the evening). Any dosage adjustments may concern the frequency of administration or the fractionation of the dose but must in any case be included within the maximum daily dosage of 600 mg. \u003cu\u003eChildren over 2 years old\u003c\/u\u003e: Fluimucil Mucolytic 100 mg granules for oral solution (with or without sugar): 1 sachet 2 to 4 times a day, depending on age. Fluimucil Mucolytic 100 mg\/5 ml, syrup: ½ scoop of syrup (5 ml), equal to 100 mg of N-acetylcysteine, 2 to 4 times a day depending on age. The duration of therapy is 5 to 10 days. \u003cb\u003eMethod of administration\u003c\/b\u003e \u003cu\u003eGranules for oral solution\u003c\/u\u003e: dissolve the contents of a sachet in a glass containing a little water, mixing as needed with a teaspoon. This results in a pleasant solution that can be drunk directly from the glass or, in the case of small children, given in teaspoons or in a bottle. The solution should be taken as soon as it is ready. \u003cu\u003eOral soluble tablets\u003c\/u\u003e: keep the tablet in the oral cavity until it has completely dissolved. \u003cu\u003eSyrup\u003c\/u\u003e: shake before use. Once opened, the syrup is valid for 15 days. Effervescent tablets: dissolve one tablet in a glass containing a little water, mixing as needed with a teaspoon. To facilitate the release of the tablet, we recommend tearing open the blister, using the side notches as indicated in the figure.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSachets of 100 and 200 granules for oral solution, 600 mg granules for oral solution, 200 mg granules for oral solution without sugar and 200 mg buccal tablets: store at a temperature not exceeding 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients suffering from bronchial asthma must be closely monitored during therapy; if bronchospasm appears, treatment with N-acetylcysteine ​​must be immediately suspended and appropriate treatment must be started. Mucolytics can induce bronchial obstruction in children under 2 years of age. In fact, the drainage capacity of bronchial mucus is limited in this age group, due to the physiological characteristics of the respiratory tract. They should therefore not be used in children under 2 years of age (see section 4.3). The use of the medicine in patients suffering from peptic ulcers or with a history of peptic ulcers requires particular attention, especially in case of simultaneous intake of other drugs with a known gastro-injurious effect. The possible presence of a sulphurous odor does not indicate alteration of the preparation but is specific to the active ingredient contained in it. The administration of N-acetylcysteine, especially at the beginning of treatment, can fluidize bronchial secretions and increase their volume at the same time. If the patient is unable to expectorate effectively, postural drainage and bronchoaspiration should be used to avoid retention of secretions. N-acetylcysteine ​​can affect histamine metabolism. Therefore, caution should be used when administering Fluimucil Mucolytic to patients with histamine intolerance, as hypersensitivity symptoms may occur. \u003ci\u003e \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003c\/i\u003e Sodium benzoate The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 15 mg of sodium benzoate for the 10 ml dose and 7.5 mg for the 5 ml dose.\u003ci\u003eParahydroxybenzoates\u003c\/i\u003e Syrups contain parahydroxybenzoates which can cause delayed allergic reactions. \u003ci\u003eSorbitol\u003c\/i\u003e The buccal tablets, 600 mg\/15 ml syrup, 600 mg granules for oral solution and 100 mg and 200 mg sugar-free granules for oral solution contain sorbitol. The sorbitol content in oral medicinal products may modify the bioavailability of other co-administered oral medicinal products. Patients with hereditary fructose intolerance should not be given these medicines. \u003ci\u003eAspartame\u003c\/i\u003e The buccal tablets, effervescent tablets, granules for oral solution 600 mg and granules for sugar-free oral solution 100 and 200 mg contain aspartame, a source of phenylalanine which may be harmful in patients with phenylketonuria. \u003ci\u003eGlucose\u003c\/i\u003e The 600 mg effervescent tablets, the 600 mg granules for oral solution and the 200 mg granules for oral solution contain glucose, patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. \u003ci\u003eSunset yellow (E110)\u003c\/i\u003e The granules for oral solution 100 mg and 200 mg contain sunset yellow (E110) which may cause allergic reactions. \u003ci\u003eSucrose\u003c\/i\u003e The granules for oral solution 100 and 200 mg contain sucrose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. \u003ci\u003eSodium\u003c\/i\u003e The buccal tablets contain 26.9 mg sodium per tablet equivalent to 1.3% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 200 mg and 600 mg effervescent tablets contain 156.9 mg sodium per dose, equivalent to 7.8% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 100 mg\/5 ml (150 ml) syrup contains 36.7 mg of sodium per 10 ml dose, equivalent to 1.83% of the WHO recommended maximum daily intake of 2 g of sodium for an adult. The 100 mg\/5 ml (150 ml) syrup contains 18.4 mg sodium per 5 ml dose, equivalent to 0.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 100 mg\/5 ml (200 ml) syrup contains 38.2 mg of sodium per 10 ml dose, equivalent to 1.9% of the WHO recommended maximum daily intake of 2 g of sodium for an adult. The 100 mg\/5 ml (200 ml) syrup contains 19.1 mg sodium per 5 ml dose, equivalent to 0.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult. The 600 mg\/15 ml syrup contains 98.31 mg of sodium per 15 ml dose equivalent to 4.9% of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. \u003ci\u003eLactose\u003c\/i\u003e The 600 mg granules for oral solution and the 200 mg granules for oral solution contain lactose. Patients suffering from rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. \u003ci\u003ePropylene glycol\u003c\/i\u003e The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 23.4 mg of propylene glycol for the 10 ml dose and 11.7 mg for the 5 ml dose. The 600 mg\/15 ml syrup contains 168 mg of propylene glycol per dose (15 ml) equivalent to 11.2 mg\/ml. \u003ci\u003eEthanol\u003c\/i\u003e The 100 mg\/5 ml syrup (150 ml and 200 ml) contains 3.85 mg of alcohol (ethanol) in every 100 ml. The dose quantity of this medicine is equivalent to less than 1 ml of beer or 1 ml of wine. The small amount of alcohol in this medicine will not produce any noticeable effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDrug-drug interaction\u003c\/u\u003e. Antitussive drugs and mucolytic agents, such as N-acetylcysteine, should not be taken at the same time as the reduction of the cough reflex could lead to an accumulation of bronchial secretions. Activated charcoal can reduce the effect of N-acetylcysteine. It is advisable not to mix other drugs with the Fluimucil Mucolytic solution. The information available regarding the antibiotic-N-acetylcysteine ​​interaction refers to in vitro tests, in which the two substances were mixed, which showed a decreased activity of the antibiotic. However, as a precaution, it is recommended to take oral antibiotics at least two hours after the administration of N-acetylcysteine, excluding loracarbef. It has been shown that the simultaneous intake of nitroglycerin and N-acetylcysteine ​​causes significant hypotension and causes dilation of the temporal artery with the possible onset of headache. If the simultaneous administration of nitroglycerin and N-acetylcysteine ​​is necessary, patients should be monitored for the appearance of hypotension which can even be severe and alerted to the possible onset of headache. \u003cu\u003ePediatric population\u003c\/u\u003e Interaction studies have only been carried out in adults. \u003cu\u003eDrug-laboratory test interactions\u003c\/u\u003e N-acetylcysteine may cause interference with the colorimetric assay method for the determination of salicylates. N-acetylcysteine ​​may interfere with urine ketone testing.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSafety profile summary\u003c\/u\u003e The adverse events most frequently associated with the oral administration of N-acetylcysteine ​​are gastrointestinal in nature. Less frequently, hypersensitivity reactions including anaphylactic shock, anaphylactic\/anaphylactoid reactions, bronchospasm, angioedema, rash and pruritus have been reported. \u003cu\u003eTabular list of adverse reactions\u003c\/u\u003e The following table shows the adverse reactions listed according to the classification and frequency system: very common (≥ 1\/10), common (≥ 1\/100 to \u003c 1\/10), uncommon (≥ 1\/1,000 to \u003c 1\/100), rare (≥ 1\/10,000 to \u003c 1\/1,000), very rare (\u003c 1\/10,000) and not known (the frequency cannot be established on the basis of available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eSystem organ class - Adverse reactions: Uncommon (≥1\/1,000; \u003c1\/100). Rare (≥1\/10,000; \u003c1\/1,000). Very rare (\u003c1\/10,000). Not known.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Adverse reactions: Hypersensitivity. Anaphylactic shock, anaphylactic\/anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Adverse reactions: Headache.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders - Adverse reactions: Tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Adverse reactions: Tachycardia.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Haemorrhage.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Bronchospasm, dyspnoea. Bronchial obstruction.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Adverse reactions: Vomiting, diarrhea, stomatitis, abdominal pain, nausea. Dyspepsia.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Adverse reactions: Urticaria, rash, angioedema, pruritus.\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the administration site - Adverse reactions: Pyrexia. Edema of the face.\u003c\/p\u003e\n\u003cp\u003eDiagnostic tests - Adverse reactions: Reduced blood pressure.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDescription of some adverse reactions\u003c\/u\u003e In very rare cases, the appearance of serious skin reactions has occurred in temporal connection with the intake of N-acetylcysteine, such as Stevens-Johnson syndrome and Lyell syndrome. Although in most cases at least one other suspected drug has been identified which is more likely involved in the genesis of the aforementioned mucocutaneous syndromes, in case of mucocutaneous alterations it is advisable to contact your doctor and the intake of N-acetylcysteine ​​must be stopped immediately. Some studies have confirmed a reduction in platelet aggregation when taking N-acetylcysteine. The clinical significance of these findings has not yet been defined. \u003ci\u003eReporting of suspected adverse reactions\u003c\/i\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been found with oral administration of N-acetylcysteine. Healthy volunteers, who took a daily dose of 11.6 g of N-acetylcysteine ​​for three months, did not experience serious adverse reactions. Doses up to 500 mg NAC\/kg body weight, administered orally, were tolerated without any symptoms of intoxication. \u003ci\u003eSymptoms\u003c\/i\u003e Overdose can cause gastrointestinal symptoms such as nausea, vomiting and diarrhea. \u003ci\u003eTreatment\u003c\/i\u003e There are no specific antidotal treatments; Overdose therapy is based on symptomatic treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAlthough the teratological studies conducted with Fluimucil Mucolytic on animals have not shown any teratogenic effect, however, as with other drugs, its administration during pregnancy and during the period of breastfeeding with breast milk should only be carried out in case of actual need.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eN-acetylcysteine does not influence the ability to drive and use machines.\u003c\/p\u003e","brand":"Zambon","offers":[{"title":"Default Title","offer_id":40731897430131,"sku":"034936106","price":11.63,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/zambon-italia-srl-fluimucil-mucolitico-200-mg-30-bustine-granulato-senza-zucchero-farmacia-dottor-tili-1213792517.webp?v=1767131148","url":"https:\/\/www.dottortili.com\/en-eu\/products\/muculcotic-fluimucil-200-mg-30-sugar-free-granulated-sachets","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}